1.47
price down icon3.31%   -0.0503
 
loading
Cellectis Adr stock is traded at $1.47, with a volume of 48,403. It is down -3.31% in the last 24 hours and up +0.68% over the past month. Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
See More
Previous Close:
$1.5203
Open:
$1.51
24h Volume:
48,403
Relative Volume:
0.16
Market Cap:
$105.97M
Revenue:
$5.15M
Net Income/Loss:
$-65.35M
P/E Ratio:
-1.0889
EPS:
-1.35
Net Cash Flow:
$-20.85M
1W Performance:
-6.96%
1M Performance:
+0.68%
6M Performance:
-21.39%
1Y Performance:
-49.31%
1-Day Range:
Value
$1.47
$1.60
1-Week Range:
Value
$1.4602
$1.60
52-Week Range:
Value
$1.10
$2.9126

Cellectis Adr Stock (CLLS) Company Profile

Name
Name
Cellectis Adr
Name
Phone
-
Name
Address
-
Name
Employee
222
Name
Twitter
@cellectis
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
CLLS's Discussions on Twitter

Compare CLLS with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CLLS
Cellectis Adr
1.47 158.46M 5.15M -65.35M -20.85M -1.35
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 27.03B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 112.64B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 40.86M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 64.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 6.07B 0 -153.72M -103.81M -2.00

Cellectis Adr Stock (CLLS) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-17-23 Initiated Bryan Garnier Buy
May-18-22 Upgrade Robert W. Baird Neutral → Outperform
Jan-06-22 Downgrade Wells Fargo Overweight → Equal Weight
Nov-30-21 Initiated JMP Securities Mkt Outperform
Nov-08-21 Downgrade William Blair Outperform → Mkt Perform
Oct-08-21 Downgrade Robert W. Baird Outperform → Neutral
Apr-28-21 Downgrade Guggenheim Buy → Neutral
Mar-16-21 Upgrade Robert W. Baird Neutral → Outperform
Aug-19-20 Upgrade Citigroup Neutral → Buy
May-12-20 Initiated Robert W. Baird Outperform
Mar-06-20 Downgrade Goldman Neutral → Sell
Oct-30-19 Resumed Guggenheim Buy
Aug-09-19 Initiated BTIG Research Buy
May-24-19 Resumed Citigroup Neutral
Mar-14-19 Initiated William Blair Outperform
Dec-19-18 Initiated Goldman Neutral
Jul-16-18 Initiated Barclays Overweight
Mar-16-18 Initiated Guggenheim Neutral
Sep-05-17 Downgrade SunTrust Buy → Hold
Sep-05-17 Reiterated Wells Fargo Outperform
Mar-02-17 Initiated Instinet Buy
Feb-28-17 Initiated Wells Fargo Outperform
Apr-05-16 Initiated Ladenburg Thalmann Buy
Mar-02-16 Initiated Sun Trust Rbsn Humphrey Buy
Jul-20-15 Initiated BofA/Merrill Buy
Apr-20-15 Initiated Jefferies Buy
Apr-20-15 Initiated Piper Jaffray Overweight
View All

Cellectis Adr Stock (CLLS) Latest News

pulisher
May 21, 2025

Cellectis S.A. announces board change and meeting By Investing.com - Investing.com India

May 21, 2025
pulisher
May 21, 2025

Cellectis S.A. announces board change and meeting - Investing.com

May 21, 2025
pulisher
May 15, 2025

European Equities See Growth In US Trade - Finimize

May 15, 2025
pulisher
May 12, 2025

Cellectis earnings beat by $0.06, revenue topped estimates - Investing.com India

May 12, 2025
pulisher
May 12, 2025

Cellectis earnings beat by $0.07, revenue topped estimates - Investing.com

May 12, 2025
pulisher
Apr 22, 2025

Cellectis Charts Course For 2025 With Boost From AstraZeneca Deal - Barchart.com

Apr 22, 2025
pulisher
Apr 11, 2025

European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading - TradingView

Apr 11, 2025
pulisher
Apr 08, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading - TradingView

Apr 08, 2025
pulisher
Apr 04, 2025

Cellectis stock touches 52-week low at $1.14 amid market challenges - Investing.com

Apr 04, 2025
pulisher
Apr 02, 2025

European Equities Traded in the US as American Depositary Receipts Flat in Wednesday Trading - TradingView

Apr 02, 2025
pulisher
Mar 20, 2025

European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading - TradingView

Mar 20, 2025
pulisher
Mar 18, 2025

European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Cellectis’s SWOT analysis: biotech firm’s stock faces CAR T challenges - Investing.com

Mar 17, 2025
pulisher
Mar 15, 2025

Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% By Investing.com - Investing.com South Africa

Mar 15, 2025
pulisher
Mar 14, 2025

Cellectis stock touches 52-week low at $1.2 amid market challenges - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

Earnings call transcript: Cellectis beats Q4 2024 expectations, stock up 10% - Investing.com India

Mar 14, 2025
pulisher
Mar 14, 2025

What Recent Market Trends Mean for Cosan S.A ADR’s (CSAN) Stock - The News Heater

Mar 14, 2025
pulisher
Mar 11, 2025

European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading - TradingView

Mar 11, 2025
pulisher
Mar 07, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Up Slightly for Week - TradingView

Mar 07, 2025
pulisher
Mar 06, 2025

Cellectis stock touches 52-week low at $1.24 amid market challenges - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading - TradingView

Mar 06, 2025
pulisher
Feb 28, 2025

European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Remain Flat for Week - TradingView

Feb 28, 2025
pulisher
Feb 27, 2025

StockNews.com Begins Coverage on Cellectis (NASDAQ:CLLS) - MarketBeat

Feb 27, 2025
pulisher
Feb 27, 2025

Cellectis earnings missed by $0.20, revenue fell short of estimates - Investing.com

Feb 27, 2025
pulisher
Feb 25, 2025

Cellectis stock touches 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa

Feb 25, 2025
pulisher
Feb 25, 2025

Cellectis stock touches 52-week low at $1.4 amid market challenges - Investing.com India

Feb 25, 2025
pulisher
Feb 24, 2025

Cellectis Presents ‘Smart CAR T’ Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025 - GlobeNewswire Inc.

Feb 24, 2025
pulisher
Feb 14, 2025

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, Up 1% for Week - TradingView

Feb 14, 2025
pulisher
Feb 07, 2025

European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading, End Week Up 3.2% - TradingView

Feb 07, 2025
pulisher
Jan 03, 2025

This Penny Stock Has 270% Upside Potential In 2025. Is It A Buy Now? - Barchart

Jan 03, 2025
pulisher
Dec 29, 2024

Analysts Predict 400% Upside Potential for This Penny Stock - Yahoo Finance

Dec 29, 2024
pulisher
Dec 26, 2024

Cellectis stock plunges to 52-week low at $1.52 amid market challenges - Investing.com India

Dec 26, 2024
pulisher
Dec 16, 2024

Cellectis stock touches 52-week low at $1.7 amid market challenges - Investing.com

Dec 16, 2024
pulisher
Dec 15, 2024

Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year - Investing.com India

Dec 15, 2024
pulisher
Nov 25, 2024

Cellectis's SWOT analysis: CAR T pioneer's stock faces pivotal year ahead - Investing.com

Nov 25, 2024
pulisher
Nov 06, 2024

Cellectis stock touches 52-week low at $1.75 amid market challenges - Investing.com

Nov 06, 2024
pulisher
Nov 05, 2024

Baird maintains $10 target on Cellectis amid strong AZN partnership - Investing.com

Nov 05, 2024
pulisher
May 06, 2024

AstraZeneca completes equity investment agreement with Cellectis - AstraZeneca

May 06, 2024
pulisher
Aug 01, 2023

CellectisADR (CLLS) Price Target Increased by 7.35% to 11.62 - Nasdaq

Aug 01, 2023
pulisher
Jun 30, 2022

Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing - Nature

Jun 30, 2022
pulisher
Feb 26, 2021

Biotech Stocks Rise After FDA Halts Test By Rival Blood Cancer Firm Cellectis - Investor's Business Daily

Feb 26, 2021
pulisher
Feb 21, 2021

Current Cathie Wood Portfolio 2021: Ark Invest Holdings - New Trader U

Feb 21, 2021
pulisher
Dec 28, 2020

Current Cathie Wood Portfolio 2020: Ark Invest Holdings - New Trader U

Dec 28, 2020
pulisher
Oct 18, 2017

7 Gene Editing Companies Investors Should Watch - Nanalyze

Oct 18, 2017
pulisher
Jul 21, 2017

AZN Stock Price and Chart — LSE:AZN - TradingView

Jul 21, 2017

Cellectis Adr Stock (CLLS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price down icon 17.27%
$31.32
price down icon 3.63%
$587.61
price up icon 1.06%
$289.96
price up icon 0.33%
$4.25
price up icon 0.48%
$75.06
price up icon 3.26%
Cap:     |  Volume (24h):